Tag: <span>GLP 1</span>

Home / GLP 1
Post

A cost-benefit analysis of GLP-1s

We’ve heard about the seemingly endless health benefits of GLP-1 medications like Ozempic and Wegovy. But we’ve also heard a lot about the high costs of the drugs. According to an analysis published Friday in JAMA Health Forum, in order to be cost-effective, the price of tirzepatide would need to go down by 30% from the current estimated annual net...

Post

Stopping GLP-1 RAs 14 days before surgery can minimize complications

by Elana Gotkine Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented at the annual meeting of the American Academy of Orthopaedic Surgeons, held from March 10 to 14 in San Diego. Shivan N. Chokshi, M.D., from the University of Tennessee...

Post

GLP-1 drugs may aid brain health, but do they bring other risks?

Share on PinterestGLP-1 drugs may protect the brain from inflammation, some studies say, but others warn they may increase depression risk. Image credit: James Manning – PA Images/Getty Images. Glucagon-like peptide-1 receptor agonists (GLP-1RAs or GLP-1) medications have skyrocketed into popularity over the past few years. Pharmaceutical companies initially released the drugs Ozempic (semaglutide) and Mounjaro (tirzepatide) to help with...

Post

Many adults stop GLP-1 therapy within a year with low restart rates, analysis finds

by Justin Jackson , Medical Xpress Credit: Unsplash/CC0 Public Domain A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults with overweight or obesity discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy within one year. Discontinuation rates were significantly higher and reinitiation rates were significantly...

Post

Considerations for Prescribing GLP-1s Get More Complicated

Sara Novak February 07, 2025 15939 Add to Email Alerts We know now that glucagon-like peptide 1 (GLP-1) drugs for obesity bring with them a whole host of other potential benefits, as well as a handful of side effects. But new research has brought a sharper focus on both the pros and the cons of...

Post

GLP-1s are no longer a “miracle fix

By Tina Reed   Illustration: Allie Carl/Axios   The luster is starting to wear off GLP-1 weight-loss drugs including Wegovy and Ozempic as more clinicians warn patients about side effects and other potential risks stemming from their surging demand.Why it matters: Research showing the drugs not only work for obesity but could lower the risk of heart attacks,...

February 13, 2025February 13, 2025by In News
Post

Some Patients — And Doctors — Turn to Microdosing GLP-1s

Kathleen Doheny; Carolyn Crist February 06, 2025 2234 As glucagon-like peptide 1 (GLP-1) receptor agonist use becomes more prevalent, patients are using them for new indications — and at new dosages. Say hello to microdosing, or taking doses lower than the recommended therapeutic amount, for various reasons: Weight maintenance, metabolic health improvements, anti-inflammation and anti-autoimmune...

Post

How Do GLP-1s Affect Cardiac Structure and Skeletal Muscle?

Ileana L. Piña, MD, MPH; Barry A. Borlaug, MD DISCLOSURES | January 28, 2025 6733 Ileana L. Piña, MD, MPH: Hello. I’m Ileana Piña, from Thomas Jefferson University in Philadelphia, Pennsylvania, and this is my blog. It’s a little bit different blog because I’m really interviewing a good friend about these glucagon-like peptide 1 (GLP-1) receptor agonists.  Some of...

Post

A Guide for Discussing GLP-1s as Obesity Treatments

John Watson January 24, 2025 5246 Added to Email Alert The arrival of drugs that mimic the gut hormone glucagon-like peptide 1 (GLP-1) has revolutionized the treatment of overweight and obesity, offering a biologic intervention that targets the root neurohormonal and genetic causes of these chronic conditions. However, the journey to successful treatment can be...

  • 1
  • 2